All News

tylenol,acetaminophen,pills,tablets

Prenatal acetaminophen linked to increased autism and ADHD

d EurekAlert!

Researchers at the Icahn School of Medicine at Mount Sinai have found that prenatal exposure to acetaminophen may increase the risk of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD), in children.

Read Article
RheumNow Podcast square

Sjögren's Graduates (8.22.2025)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, etc.

Read Article
Sjogren.eye.mouth

It's now called Sjögren Disease!

d Jack Cush, MD

Sjögren syndrome is now Sjögren disease, according to recommendations stemming from the 2023 International Rome consensus for the nomenclature of Sjögren disease.

Read Article
Pills.JIA_.png

Antibiotics are not linked to Autoimmune disease in kids

d EurekAlert!

The global incidence of autoimmune diseases among children has increased over the past few decades.

Read Article
heart.EKG_.CVD_.jpg

Cardiovascular Sequelae in Adults After Kawasaki Disease

d Jack Cush, MD

A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s. 

Read Article
PsA.Hands_.jpg

Safety of Combination Targeted Therapies in Psoriatic Arthritis

d MedPage Today

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased risk of serious infections, insurance claims data indicate.

Read Article
Future,space,time

Rheums Speak: Future of Rheumatoid Arthritis

d Jack Cush, MD

The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.

Read Article
FDA has granted Soligenix "Orphan Drug Designation" to study dusquetide in the treatment of Behçet's dz, based on an 8 patient proof of concept Phase 2a trial. Not yet FDA approved, dusquetide is a short peptide innate defense regulator (IDR). Behcets affects 18K in USA and https://t.co/bTTK9GrYBq
Dr. John Cush RheumNow ( View Tweet)
TriNetX database study shows Beta blocker use assoc w/ more hip replacements (THA). 23K propensity matched pts (mean age 69) on or off BB compared. After 3 yrs BB use was assoc w/ higher risk of THA (HR 1.49; 1.4–1.59), esp w/ alpha-BBs (HR 1.64) https://t.co/W6ocMYI653 https://t.co/EiQ4WH94cD

Links:

Dr. John Cush RheumNow ( View Tweet)
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed infusions(RTX 1000 mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades 1, 2) infusion Rxns; only 6 Grade 3 Rxns https://t.co/uVKuhhc80F https://t.co/Hgqspu3wUm

Links:

Dr. John Cush RheumNow ( View Tweet)
New IDSA recommendation: In hospitalized on systemic steroids w/ severe, critical, progressing COVID-19, when baricitinib or tocilizumab are not available, IDSA guideline panel suggests infliximab. https://t.co/ZCkkZXUDpi https://t.co/gbgkvj5R8Y

Links:

Dr. John Cush RheumNow ( View Tweet)
ChildCAPTURE & BioCAPTURE registry studies of 117 pediatric & 243 young adult Psoriasis pts on biologics (753.4 Pt-Yrs) shows no sex differences in clinical responses, but shows females have more adverse events than males (both cohorts) https://t.co/5at9vCqwIO https://t.co/ScJkIH9G31

Links:

Dr. John Cush RheumNow ( View Tweet)
Uncertainty with immunosuppressive for idiopathic inflammatory myopathies A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for IIM. https://t.co/evkwbX6U9j https://t.co/2s0Z9Y9Umm

Links:

Dr. John Cush RheumNow ( View Tweet)
Claims data study of 82 399 PsA pts - 542 on combo targeted Rx >3 mos (200 > 6mos). 2 most common combos of apremilast w/ TNFi or IL-17i. Use of combo targeted Tx was not assoc. w/ more serious infxn (RRs 0.53; 0.17-1.63) or opportunistic infx (RR 1.00; 0.09-11.02) @ 3 or 6 mos https://t.co/mkvq1lqt9Y
Dr. John Cush RheumNow ( View Tweet)
RCT of 2331 chronic MSK pain pts showed that telehealth Cognitive behavioral therapy (CBT) (health coach) superior to self-care (Pain trainer) or usual care at achieving a >30% reduction in pain (32% vs 26.6% vs 20.8% respectively) & benefits were sustained at 12 months. https://t.co/a69zPsJslH
Dr. John Cush RheumNow ( View Tweet)
The global autoimmune disease treatment market was valued at $7 billion USD in 2024 and is expected to rise to ~$11 billion by 2030 and reach $12.6 billion by 2032 https://t.co/C5IQ0hUvQE https://t.co/RjbMo5cCOl

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Rheumatology Thread for Busy GPs: Post 1 Early inflammatory arthritis(IA): the 3–3–3 rule •Onset ≤3 months •Morning stiffness ≥30–60 minutes •≥3 swollen joints (MCP/MTP common) If present, manage as IA: urgent rheum referral; NSAIDs if no contraindications. https://t.co/hcoumX1ZVY

Links:

Aravind Palraj Rheumat_Aravind ( View Tweet)
Gout Education Card for Patients - Diagnosis & Management #2 https://t.co/uppST8OBLZ https://t.co/sLF5WPeuA5

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Education Card for Patients - Info & Rules #1 https://t.co/uppST8OBLZ https://t.co/3Ry3erNJCL

Links:

Dr. John Cush RheumNow ( View Tweet)
TNF Inhibitors in Takayasu's Arteritis A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis. https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×